Jazz’s Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) Receives the US FDA’s Approval for Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Shots:

  • The approval is based on clinical data from an ongoing P-II/III JZP458-201 trial evaluating Rylaze in pediatric and adult patients aged ≥1mos. with ALL or LBL who are allergic to the E. coli-derived asparaginase. Rylaze has approved under the RTOR program
  • Additionally, recent data from a Children’s Oncology Group retrospective analysis in ~8,000 patients showed that the patients without asparaginase treatment due to associated toxicity had lower survival outcomes
  • The therapy is expected to be commercially available in mid-July in the US. The FDA has granted ODD to Rylaze for ALL/LBL in June’21 & FTD in Oct’19

Click here to­ read full press release/ article | Ref: PR Newswire | Image: Life Sciences IP Review

The post Jazz’s Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) Receives the US FDA’s Approval for Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma first appeared on PharmaShots.